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Abstract Alterations in the functions of brain gamma-
aminobutyric acid (GABA) inhibitory system and a dis-
tortion in the balance between excitatory and inhibitory
synaptic transmission have been hypothesized to be pos-
sible causes of mood disorders. Experimental evidence
points to modifications of GABAergic transmission as a
result of prolonged treatment with antidepressant drugs,
however, the influence of the tricyclic antidepressant
imipramine on inhibitory synaptic transmission in the rat
cerebral cortex has not yet been investigated. Therefore, in
the present study the effects of single and repeated
administration of imipramine were evaluated ex vivo in
slices of the rat frontal cortex using electrophysiological
approach. In slices prepared 2 days after the last drug
administration from animals receiving imipramine for
14 days (dose 10 mg/kg p.o., twice daily) the mean fre-
quency of spontaneous inhibitory postsynaptic currents
(sIPSCs) recorded from layer II/III pyramidal neurons was
decreased, while the mean amplitude of sIPSCs was
increased. These effects were absent in slices obtained
from rats which received imipramine once. Application of
N,N0-dibenzhydrylethane-1,2-diamine dihydrochloride
(AMN 082), a selective mGluR7 allosteric agonist, to the
slice incubation medium resulted in a decrease in the mean
frequency of sIPSCs in preparations obtained from repe-
ated imipramine-treated animals, in contrast to slices
originating from control rats where no AMN 082-induced
effects were observed. Repeated imipramine treatment
reduced protein density levels of the three tested GABAA
receptor subunits: a1, b2 and c2. These data indicate that
repeated treatment of normal rats with imipramine results
in a modification of the release mechanism of GABA from
presynaptic terminals and its modulation by mGluR7
receptors as well as in an alteration in GABAA receptor
subunit protein levels in the rat cerebral cortex.
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Introduction
A large proportion of the population affected by depression
is not responding adequately to current treatments. It has
been estimated that only one-third of patients respond to
the first medication prescribed and that treatment-resistant
depression may represent up to 50–70 % of cases
(reviewed in: Duric and Duman 2012; Jenkins and Goldner
2012). Despite many years of research focusing on the
efficacy of antidepressant drugs, the underlying mecha-
nisms remain incompletely understood. At the cellular
level, the primary effects of administration of a majority of
currently used antidepressants seem to involve modulation
of monoamine neurotransmission (reviewed in: Slattery
et al. 2004; Lo´pez-Mun˜oz and Alamo 2009; Murrough and
Charney 2012). However, growing experimental evidence
points to other effects of prolonged treatment with anti-
depressants, in particular to modifications of excitatory and
inhibitory transmission mediated by glutamate and gamma-
aminobutyric acid (GABA), respectively. These views are
consistent with the data documenting alterations in the two
brain amino acid neurotransmitter systems and a distortion
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in the balance between them, as possible causes of mood
disorders (Sanacora et al. 2004; reviewed in: Skolnick et al.
2009; Croarkin et al. 2011; Hashimoto 2011; Luscher et al.
2011). Regarding the glutamatergic system, it has been
shown that depressive disorders are accompanied by
alterations in ionotropic AMPA and NMDA receptor-
mediated synaptic transmission (reviewed in: Bleakman
et al. 2007; Pittenger et al. 2007; Sanacora et al. 2012) and
by altered levels of metabotropic glutamate receptors
(Feyissa et al. 2010). Preliminary data indicate that
symptoms of depression may be alleviated by treatments
with drugs inhibiting the release of glutamate, lamotrigine
and riluzole, as well as with the NMDA receptor antago-
nist, ketamine (Berman et al. 2000; Carlson et al. 2006;
Zarate et al. 2010; Duman and Voleti 2012; Mathew et al.
2012).
Less is known about postulated depression-related
modifications of the GABAergic system. Several studies
did not find difference in the level of GABA in the cere-
brospinal fluid of depressed patients in comparison with
normal subjects but some researchers reported a reduction
of the level of GABA in patients suffering from depression
(reviewed in: Tunnicliff and Malatynska 2003, Croarkin
et al. 2011, Luscher et al. 2011). Proton magnetic reso-
nance spectroscopy provided evidence for a reduced level
of GABA in certain cerebral cortical areas of depressed
patients (Sanacora et al. 1999; Price et al. 2009). Major
depression has also been shown to be accompanied by
upregulation of several GABAA receptor subunits (Chou-
dary et al. 2005). These data are consistent with results
obtained from animal models of human depression. For
example in the olfactory bulbectomized rats the density of
frontal cortical GABAA receptors is decreased and this
effect is reversed by a chronic treatment with antidepres-
sants, including desipramine, an active metabolite of
imipramine (Dennis et al. 1994). A depressive-like
behavior has been found to characterize GABAA receptor
c2 subunit-deficient mice (Shen et al. 2010). A decrease in
the level of GABA, among other changes, has been found
to occur in the prefrontal cortex of rats subjected to the
chronic mild stress and chronic social defeat stress
(Venzala et al. 2012). Chronic mild stress-related dys-
function of the GABAergic transmission was also revealed
in the rat dentate gyrus (Holm et al. 2011).
Imipramine, a prototypic tricyclic antidepressant, is
regarded one of the most effective drugs and is still used to
treat severe cases of depression although it causes
unwanted side effects (reviewed in: Lo´pez-Mun˜oz and
Alamo 2009). Imipramine acts as an inhibitor of serotonin
and norepinephrine reuptake (reviewed in: Schloss and
Williams 1998; Slattery et al. 2004). After the adminis-
tration imipramine is rapidly metabolized with the forma-
tion of desipramine and other active hydroxy metabolites
(Daniel et al. 1981; Potter et al. 1982; Gram 1988). A
complex picture of changes in the expression pattern of
numerous genes has been found to result from the treat-
ment of rats with imipramine (Palota´s et al. 2004) but one
important outcome of repeated administration of imipra-
mine involves a reduction in radioligand binding to
N-methyl-D-aspartate (NMDA) receptors in the cerebral
cortex suggestive of a suppression of glutamatergic trans-
mission (Nowak et al. 1993). We have previously shown
using electrophysiological recording techniques that repe-
ated imipramine treatment of rats results in an attenuation
of the release of glutamate from presynaptic terminals and
an alteration in the reactivity of postsynaptic ionotropic
glutamate receptors in the frontal cortex (Bobula et al.
2003; Bobula and Hess 2008; Tokarski et al. 2008),
However, the influence of imipramine on inhibitory syn-
aptic transmission in the rat cortex has not yet been
investigated. Therefore, in the present study we aimed at
finding the effects of repeated imipramine administration
on spontaneous inhibitory postsynaptic currents (sIPSCs)
recorded from frontal cortical pyramidal cells and on the
protein amount of selected subunits of the GABAA
receptor. We chose a1, b2 and c2 subunits since GABAA
receptors containing these subunits predominate in the
cortex (Johnstone 2005; Luscher and Keller 2004; Skilbeck
et al. 2010).
It has been reported that the major depressive disorder
and anxiety disorders might be accompanied by alterations
in the gene coding the metabotropic glutamate receptor 7
(mGluR7; reviewed by: Hamilton 2011), which is widely
distributed in the human brain, including the frontal cortex
(Makoff et al. 1996). This receptor appears to be located
predominantly on presynaptic nerve terminals where it
modulates the release of GABA and glutamate (Summa
et al. 2012, reviewed in: O’Connor et al. 2010). Its selec-
tive agonist, N,N0-dibenzhydrylethane-1,2-diamine dihy-
drochloride (AMN 082), has been shown to induce
anxiolytic-like and antidepressant-like effects in animal
models (reviewed in: O’Connor et al. 2010; Sukoff Rizzo
et al. 2011). In order to get insight into the influence of
repeated imipramine treatment on mGluR7 receptor-
dependent modulation of GABA release we tested the




Experimental procedures were approved by the Animal
Care and Use Committee at the Institute of Pharmacology,
Polish Academy of Sciences, and were carried out in
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accordance with the European Community guidelines for
the use of experimental animals and national law. Male
Wistar rats, weighing approx. 120 g at the beginning of the
experiment, were obtained from Charles River, Germany.
Animals were housed in groups and maintained on a 12 h
light/dark schedule with standard food and tap water
available ad libitum.
Imipramine treatment and slice preparation
Two experimental and two control groups, each consisting
of 8 rats, were investigated. Imipramine (Sigma-Aldrich),
dissolved in water, was administered per os by using the
gavage technique (dose 10 mg/kg, volume 2 ml/kg) either
once (termed: single administration) or twice daily for
14 days (termed: repeated administration; Maj et al. 1982).
The rats of the two control groups received water either
once or twice daily for 14 days but otherwise they were
handled identically and were investigated concurrently
with imipramine-treated animals. It has earlier been shown
that this procedure of drug administration per se does not
influence the outcome of experiments (Bobula et al. 2003;
Zahorodna et al. 2006).
Two days after the last imipramine administration rats
were decapitated, their brains were quickly removed and
placed in an ice-cold artificial cerebrospinal fluid (aCSF)
containing (in mM): 130 NaCl, 5 KCl, 2.5 CaCl2, 1.3
MgSO4, 1.25 KH2PO4, 26 NaHCO3, 10 D-glucose and
bubbled with the mixture of 95 % O2–5 % CO2. Frontal
cortex slices (420 lm thick) from one hemisphere were cut
in the coronal plane using a vibrating microtome (Leica
VT1000). Slices were stored submerged in aCSF at
32 ± 0.5 C and then used for electrophysiological
experiments. The other brain hemisphere was placed on the
dry ice and stored at -80 C for later biochemical analysis.
Whole-cell recording and analysis of sIPSCs
A slice was placed in the recording chamber and super-
fused at 3 ml/min with warm (32 ± 0.5 C), modified
aCSF of the following composition (in mM): 132 NaCl, 2
KCl, 1.25 KH2PO4, 26 NaHCO3, 1.3 MgSO4, 2.5 CaCl2,
and 10 D-glucose 10, bubbled with 95 %O2–5 %CO2.
Neurons were visualized using Zeiss Axioskop upright
microscope using Nomarski optics, a 409 water immersion
lens and an infrared camera (Tokarski et al. 2008). The
neurons were sampled from sites located approx. 2 mm
lateral to the midline and approx. 0.3 mm below the pial
surface (layer II/III). Patch pipettes were pulled from
borosilicate glass capillaries (Clark Electromedical Instru-
ments) using Sutter Instrument P97 puller. The pipette
solution contained (in mM): 130 K-gluconate, 5 NaCl, 0.3
CaCl2, 2 MgCl2, 10 HEPES, 5 Na2-ATP, 0.4 Na-GTP, and
1 EGTA. Osmolarity and pH were adjusted to 290 mOsm
and 7.2, respectively. Pipettes had open tip resistance of
approx. 6 MX. Signals were recorded using the SEC 05LX
amplifier (NPI), filtered at 2 kHz and digitized at 20 kHz
using Digidata 1322A interface and Clampex 9.2 software
(Molecular Devices). Pyramidal cells were identified by the
shape of the soma and the presence of a prominent apical
dendrite as well as the regular spiking pattern showing
adaptation in response to a depolarizing current pulse in the
current clamp mode.
The neurons were voltage-clamped at 0 mV and sIPSCs
were recorded for 8 min (Tokarski et al. 2007). Sponta-
neous IPSCs were detected off-line and analyzed using
Mini Analysis software (Synaptosoft). Data were accepted
for analysis when the access resistance ranged between 15
and 18 MX and it was stable (\25 % change) during
recording. In part of experiments, after recording of sIPSCs
for 4 min slices were perfused with the modified aCSF
containing 1 lM AMN 082 (Sigma-Aldrich), a selective
mGluR7 allosteric agonist. 10 min after the introduction of
AMN 082 sIPSCs were again recorded for 4 min. In a
subset of slices, 0.5 lM tetrodotoxin (TTX, Sigma-
Aldrich) and bicuculline methiodide (10 lM, Tocris Bio-
science) were added to the modified aCSF.
Western blotting
Tissue samples were homogenized in ice-cold RIPA buffer
(Sigma-Aldrich) containing phenylmethane-sulfonyl fluo-
ride, sodium orthovanadate, protease inhibitor cocktail,
phosphatase inhibitor cocktail 1, phosphatase inhibitor
cocktail 2 and 5 % glycerol. The homogenate was centri-
fuged at 14,000 rpm for 20 min at 4 C to obtain the crude
membrane fraction. Protein concentration was determined
using the BCA protein assay kit (Pierce Biotechnology,
Inc.). A standard curve was generated and then absorbance
of samples was measured with the Multiscan Spectrum
Microplat Spectrophotometer (Thermo Labsystems).
Supernatant form all samples was diluted with RIPA buffer
to obtain the same protein concentration in 150 ll of
the solution. Samples were boiled for 7 min at 99 C in
Laemmli (Bio-Rad) sample buffer with 2-mercaptoethanol
(Sigma-Aldrich). To separate proteins, sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
was performed first on 4 % upper gels (90 V, 30 min)
to condense samples and then on 7.5 % lower gels
(145 V, 60 min) with the Mini Protean Tetra Cell appara-
tus (Bio-Rad). Next, proteins were transferred to nitrocel-
lulose membranes (Bio-Rad) by electrophoresis in transfer
buffer containing 20 % methanol, at 90 V, during 1 h
(Mini Protean Tetra Cell; Bio-Rad). Following transfer, the
membranes were washed in Tris-buffered saline (TBS; 29,
10 min) and immersed in blocking solution consisting of
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3 % albumin from bovine serum (Sigma-Aldrich) and
TBST, for 60 min at room temperature. Afterwards, the
membranes were incubated with an affinity-purified poly-
clonal antibodies against the following GABAA receptor
subunits: a1 (1:200, from goat; Santa Cruz Biotechnology,
Inc.), b2 and c2 (1:1,000, from rabbit; Millipore) in 1 %
albumin—TBST at 4 C overnight. On the next day the
membranes were incubated for 60 min at room tempera-
tures, then washed two times for 10 min in TBST and two
times for 10 min in 1 % albumin solution. The membranes
were incubated with horseradish peroxidase-conjugated
secondary antibody (1:2,000, Vector Laboratories) in 1 %
albumin—TBST, for 60 min at room temperature. The
secondary antibody used for the a1 subunit was an anti-goat
antibody, whereas the secondary antibody used for the b2
and c2 subunits was an anti-rabbit antibody. The mem-
branes were washed four times for 15 min in TBST.
Proteins were detected using chemiluminescent detec-
tion method (Immun-Star HRP). The membranes were
exposed to luminol for 4 min. Luminol was activated with
an oxidant (horseradish peroxidase) and irradiation and
pictures were made with FujiLas 4000. The signal of the
specific band was expressed as the optical density level.
Results were standardized and presented as percentage
change from the control value. Signals obtained in the
same membrane but area different than bands were sub-
tracted for background correction (Kharlamov et al. 2008;
Leung et al. 2002).
Statistics
All results are expressed as mean ± SEM. Statistical
analysis involved pairs of comparisons between experi-
mental versus control groups and it was carried out using
Student’s t test for sIPSCs and Western blotting data, and
paired t test—in experiments where AMN 082 was applied.
Results
The cells included in the analysis exhibited a regular
spiking firing pattern in response to a depolarizing current
pulse and no spontaneous spiking activity (not shown). At
the holding potential of 0 mV sIPSCs were recorded as
inward currents (Figs. 1a, b; 2a). To test what fraction of
spontaneous IPSCs represented spiking activity-indepen-
dent miniature IPSCs (mIPSCs) in a sample of five cells
spontaneous events were recorded before and after addition
of 0.5 lM TTX to block action potentials. In the presence
of TTX the mean frequency of IPSCs decreased to
86.2 ± 9.8 % of baseline (Fig. 1a1, a2), but this change
was not statistically significant (p [ 0.05) which indicates
that the majority of recorded spontaneous events
corresponded to mIPSCs. After addition of 10 lM bicu-
culline methiodide spontaneous events disappeared
(Fig. 1a3) confirming that they represented GABAA
receptor-dependent currents.
There was no significant difference between control
neurons and cells in slices originating from imipramine-
treated rats either in the resting membrane potential or in
the input resistance (Table 1). There was also no difference
in the mean frequency and the mean amplitude of sIPSCs
in neurons originating from control animals and those
which received a single dose of imipramine (Fig. 1c, d). In
contrast, in slices prepared from repeated imipramine-
treated rats the mean sIPSCs frequency was decreased and
the mean sIPSCs amplitude—increased, in comparison to
control preparations (Fig. 1c, d). There was no significant
difference between control neurons and cells in slices
originating from either single or repeated imipramine-
treated rats in the parameters characterizing the kinetics of
sIPSCs: the rise time and the decay time constant
(Table 2).
While in the control group the application of AMN 082
to the aCSF induced no significant change in the mean
frequency of sIPSCs, in cells originating from repeated
imipramine-treated animals AMN 082 application reduced
the mean frequency of sIPSCs (Fig. 2a, b).
Western blot analysis revealed that repeated adminis-
tration of imipramine reduced protein density levels of all
three tested GABAA receptor subunits: a1, b2 and c2
(Fig. 3b).
Discussion
We have found that a single dose of imipramine (10
mg/kg) did not affect sIPSCs, whereas the 2 week-long
treatment resulted in a decrease in the mean frequency and
an increase in the mean amplitude of sIPSCs. We have not
determined the plasma level of imipramine, however, the
level of imipramine administered in a dose of 10 mg/kg
either once or twice a day for 14 days has been measured in
blood and brain tissue by Daniel et al. (1981). These
investigators have found that within 1 h after a single
intraperitoneal injection the concentration of imipramine in
the plasma reaches about 0.5–0.6 lg/ml and then it
decreases below the detection level within next 9 h. After
chronic treatment the maximum level of imipramine after
its last administration was higher (approx. 0.8 lg/ml) and
the elimination of the drug was slowed down. The con-
centration of imipramine in the brain has been found to be
about ten times higher than in blood and it has been con-
cluded that during repeated administration imipramine, and
its metabolite desipramine, are continuously present in the
brain tissue at concentrations which inhibit noradrenaline
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and serotonin uptake. When imipramine is administered
orally the desipramine/imipramine concentration ratio in
the brain is higher due to the demethylation of imipramine
in the liver (Maj et al. 1982).
While the amplitude of spontaneous postsynaptic
currents is determined by a combination of pre- and
postsynaptic factors, a decreased frequency of sIPSCs in
principle reflects either reduced firing of presynaptic cells
or decreased neurotransmitter release either due to a
change in release probability and/or change in the number
of release sites. Since only a non-significant decrease in
sIPSCs frequency was observed after addition of TTX to
aCSF in a subset of cells, demonstrating that most of the
recorded spontaneous events corresponded to spike-inde-
pendent mIPSCs, we consider the possibility that observed
effects result from a change in spiking activity of presyn-
aptic neurons unlikely. Therefore, a decrease in the fre-
quency of sIPSCs most likely reflects repeated imipramine
treatment-related modification of the mechanism of GABA
release from presynaptic terminals. We have previously
Fig. 1 Repeated imipramine-induced changes in the mean frequency
and the mean amplitude of spontaneous IPSCs in layer II/III
pyramidal cells. An example of recording from an individual neuron
in a slice prepared from control, untreated animal in the aCSF (a1)
and after addition of TTX (a2) as well as bicuculline methiodide (a3).
Upward deflections represent individual sIPSCs. b1 An example of
recording from another control cell and b2 from the cell originating
from repeated imipramine-treated rat. b3 Superposition of averaged
sIPSCs from the raw recordings whose parts are shown in b1 and b2 (1
control; 2 repeated imipramine-treated). c Mean (±SEM) frequency
of sIPSCs in control neurons (Con) and neurons from single (Imi 19)
and repeated imipramine (Imi 149)-treated animals. d Mean (±SEM)
amplitude of sIPSCs. Abbreviations as in c. *p \ 0.05, Student’s t test
Fig. 2 Effect of 1 lM AMN
082 on the frequency of sIPSCs.
a Examples of sIPSCs (upward
deflections) recording from
slices obtained from control
(Con) and repeated imipramine-
treated (Imi 149) rats and the
effects of AMN 082 (AMN)
addition to aCSF. b Mean
(±SEM) frequency of sIPSCs
after AMN 082 application in
the control (Con) and repeated
imipramine-treated (Imi 149)
group. Number on bars
represent numbers of cells
in each group; *p \ 0.05,
paired t test
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shown that the same treatment results in an approximately
twofold decrease in the frequency of glutamatergic spon-
taneous excitatory postsynaptic currents (sEPSCs) in rat
frontal cortical pyramidal cells (Tokarski et al. 2008).
Thus, in the frontal cortex repeated imipramine treatment
appears to exert a similar effect on the release from pre-
synaptic terminals of both the excitatory and the inhibitory
amino acid.
The available data on imipramine-induced modifications
of neurotransmitter release mechanisms are scarce. Chronic
imipramine induced a decrease of potassium-stimulated
glutamate outflow in rat prefrontal cortex (Michael-Titus
et al. 2000). In the hippocampus, treatment with antide-
pressant drugs, including desipramine, reduced the protein–
protein interaction between syntaxin 1 and a-calcium/cal-
modulin-dependent protein kinase II, thought to promote
glutamate release, and simultaneously increased the inter-
action between syntaxin and Munc-18, thought to reduce
release (Bonanno et al. 2005). It is conceivable that similar
mechanisms might be involved in GABAergic synapses in
the frontal cortex but it should be noted that these authors
found that while the tested drugs reduced the release of
glutamate in the hippocampus, GABA release remained
unchanged.
One possible mechanism of the modification of the
release of GABA relates to alterations in modulatory
effects imposed by presynaptic mGluR7 receptors. The
present results demonstrate that while under control
experimental conditions 1 lM AMN 082 did not affect the
frequency of sIPSCs, in slices obtained from repeated
imipramine-treated rats the mGluR7 receptor agonist
decreased the mean sIPSCs frequency. Activation of
mGluR7 receptors inhibits neurotransmitter release through
a reduction in intracellular cAMP level and a decrease in
presynaptic Ca2? influx (Millan et al. 2002). The inhibitory
effect of AMN 082 on the release of GABA from pre-
synaptic terminals is dose-dependent (Summa et al. 2012).
Since it has been demonstrated that imipramine, but not the
selective serotonin reuptake inhibitor (SSRI), citalopram,
administered repeatedly for 21 days produced no change in
mGluR7 immunoreactivity in the rat cortex (Wieronska
et al. 2007), we conclude that repeated imipramine appears
to induce a functional sensitization of this system at the
post-receptor level. It remains to be established whether
other mechanisms contribute to the observed effect of
repeated imipramine administration on presynaptic GABA
release machinery.
Earlier research demonstrated that 21 days-long con-
stant, subcutaneous infusion of imipramine did not produce
changes in the level of mRNAs encoding GABA synthe-
sizing enzymes, GAD65 and GAD67, the GABA mem-
brane transporter GAT-1 (SLC6A1 according to the HUGO
Gene Nomenclature Committee) as well as the catabolizing
Table 1 Basic parameters of recorded cells
Group Vm (mV) Rm (MX) n
Con 19 -70.40 ± 1.34 39.01 ± 3.25 9
Imi 19 -69.15 ± 1.16 37.30 ± 5.53 9
Con 149 -70.00 ± 1.18 40.15 ± 2.81 13
Imi 149 -71.07 ± 1.09 37.93 ± 1.80 13
Data are presented as the mean ± SEM. Differences between values
for neurons in experimental and control groups are not significant
(p [ 0.05)
Vm resting membrane potential, Rm input resistance, Con control
neurons, Imi neurons originating from animals receiving imipramine
once (19) or for 14 days (149)
Table 2 Rise time and decay time constant (s) of averaged sIPSCs
Group Rise time (ms) s (ms) n
Con 19 2.90 ± 0.14 12.33 ± 1.52 9
Imi 19 2.79 ± 0.10 11.27 ± 0.79 9
Con 149 3.05 ± 0.26 11.33 ± 0.81 13
Imi 149 3.14 ± 0.11 12.46 ± 1.10 13
Data are presented as the mean ± SEM. Rise time was measured
between 10 and 90 % of maximum amplitude. Decay time constant
(s) was determined as the time required for the current to decay to
36.8 % of its maximum value. Differences between values for neu-
rons in experimental and control groups are not significant (p [ 0.05)
Con control neurons, Imi neurons originating from animals receiving
imipramine once (19) or for 14 days (149)
Fig. 3 Western blot analysis of GABAA receptor subunits proteins.
a Computerized scans of representative Western immunoblots
illustrating the ratio of a1 (51 kDa), b2 (55 kDa) and c2 (46 kDa)
subunit protein bands in repeated imipramine-treated (Imi) and
control (Con) groups. b Bars representing summary results of
densitometric analysis of a1, b2 and c2 subunit proteins from the
cortex of repeated imipramine-treated rats (mean ± SEM), relative to
the tissue from control rats. **p \ 0.01, Student’s t test. In each
barn = 6–8
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enzyme, GABA transaminase in the rat cortex (Lai et al.
1998). However, it cannot be excluded that the observed
increase in the mean amplitude of sIPSCs is a result of an
increased neurotransmitter content of synaptic vesicles. To
our knowledge there is no available data for the level and
the activity of the vesicular GABA transporter (VGAT/
SLC32A1) after antidepressant treatments but, for exam-
ple, the antipsychotic drug clozapine increases the amount
of VGAT/SLC32A1 in rat frontal cortex (Bragina et al.
2007). On the other hand, rats with the genetic deletion of
the serotonin transporter, expressing an anxious and
depressive phenotype, demonstrated a.o. a reduced level of
VGAT/SLC32A1 (Guidotti et al. 2012). In an animal
model of stress and depression the expression level of
vesicular glutamate transporter VGLUT1/SLC17A7 was
reduced in the rat cortex (Zink et al. 2010). Moreover,
decreased expression of VGLUT1/SLC17A7 results in an
increased depressive-like behavior (Garcia-Garcia et al.
2009) and several antidepressant drugs, including desipra-
mine, enhanced VGLUT1/SLC17A7 expression in the
cortex (Moutsimilli et al. 2005). Thus, we hypothesize that
in our experiments a similar effect on the vesicular trans-
porter in GABAergic synapses might have been induced by
imipramine.
We have found that repeated imipramine treatment
resulted in a similar degree of a decrease in protein density
levels of a1, b2 and c2 subunits in rat frontal cortex. Since
these subunits together build the most abundant GABAA
receptor subtype in the cortex (Johnstone 2005; Luscher
and Keller 2004; Skilbeck et al. 2010), this result is con-
sistent with the downregulation of this receptor subtype.
The effects of imipramine on expression of GABAA
receptors in rat cortex have not been investigated before. In
the brainstem, chronic imipramine induced an increase in
the level of mRNAs of a3, b1 and c2, but not other, subunits
(Tanay et al. 2001). Differences in the experimental design
and in the investigated brain area may account for this
discrepancy. It is conceivable that the putative downregu-
lation of GABAA receptor subunits reflects a compensatory
process related to a postulated increase in the neurotrans-
mitter content of synaptic vesicles.
Summing up, these data show that imipramine, admin-
istered repeatedly, modifies the release of GABA from
presynaptic terminals in a complex way, by reducing the
mean frequency but increasing the mean amplitude of
sIPSCs, and reduces protein amount of the tested GABAA
receptor subunits in the rat frontal cortex. These results do
not easily fit with the current GABAergic hypothesis of
depression which implicates the deficit in the function of
the GABAergic system within the hippocampus and other
brain regions in the pathophysiology of the illness and at
least partial reversal of this deficit by antidepressants in
human patients (reviewed in: Croarkin et al. 2011; Luscher
et al. 2011). Also studies employing animal models of
depression point to a reduction in the level of GABAergic
markers and an enhancement of GABAergic transmission
due to chronic treatment with antidepressants (Dennis et al.
1994; Shen et al. 2010; reviewed in: Luscher et al. 2011).
However, it should be noted that the present work was
conducted using normal, healthy animals. It has been
shown that chronic treatment with the SSRI, fluoxetine,
reduces GABAergic transmission in the visual cortex
(Maya Vetencourt et al. 2008) and reduces evoked IPSCs
in the prefrontal cortex of normal rats (Zhong and Yan
2004). Thus, it is conceivable that in rats representing one of
the animal models of depression, for example subjected to a
chronic stress, the effects of imipramine on GABAergic
transmission in the frontal cortex might be different. This
possibility remains to be investigated in future studies.
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